+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Plasma Protease C1-inhibitor Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 4896090
  • Report
  • January 2020
  • Region: Global
  • 110 pages
  • Mordor Intelligence
until Mar 31st 2020
1 of 4


  • BioCryst Pharmaceuticals
  • Centogene AG
  • CSL Behring LLC.
  • MORE
Market Overview

Global Plasma Protease C1-inhibitor Treatment Market is expected to experience significant growth over the forecast period due to the growing incidence of hereditary angioedema (HAE). Hereditary angioedema is a potentially life-threatening genetic condition with an incidence between 1 in 10,000 and 1 in 50,000 people according to HAE International (HAEi), the global umbrella organization for the world’s HAE patient groups. Additionally, increasing R&D investments, the discovery of inhibitor drugs, increasing product approvals promising pipeline drugs and novel therapies for the treatment of hereditary angioedema are the few other factors driving the market globally.

Scope of the Report

Plasma protease C1 inhibitor (C1 Inh) is a member of the serpin family of protease inhibitors and related proteins, and its mechanism of action is identical to those of the other protease inhibitor members of the family. SERPING1 forms a proteolytically inactive stoichiometric complex with the C1r or C1s proteases. Which will play a vital role in the regulation of blood coagulation, complement activation, generation of kinins and fibrinolysis. It is also an efficient FXIIa inhibitor. Mutations of the SERPING1 gene are associated with adult macular degeneration which causes Hereditary Angioedema (HAE).

Key Market Trends

Selective Bradykinin B2 Receptor Antagonist Segment is Expected to Witness Healthy CAGR Over the Forecast Period
  • A bradykinin B2 receptor antagonist used to treat acute episodes of swelling and inflammation associated with hereditary angioedema (HAE).
  • In 2011, Icatibant (Firazyr), a selective bradykinin B2 receptor antagonist, was approved by the US Food and Drug Administration for the treatment of acute attacks HAE in adults. Approval was based on 3 double-blind, randomized, controlled clinical trials known as For Angioedema Subcutaneous Treatment (FAST) 1, 2, and 3.
  • In September 2019, Pharvaris received $66 Million Series B Financing to Advance the Clinical Development of novel oral B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other B2-receptor-mediated indications.
North America dominates the Global Plasma Protease C1-inhibitor Market
  • North America dominates the global Plasma Protease C1-inhibitor market owing to the rising Hereditary Angioedema (HAE). Presence of well-established healthcare infrastructure, an increasing number of product approvals, and major market players providing effective treatment options to the patients suffering from Hereditary Angioedema (HAE) in North America.
  • According to DiscoverHAE, it is estimated that 6,000 people in the United States live with HAE currently.
  • In June 2017, CSL Behring received U.S. Food and Drug Administration (FDA) approval for its HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]), the first and only subcutaneous therapy indicated for routine prophylaxis to prevent hereditary angioedema (HAE) attacks in adolescent and adult patients.
Competitive Landscape

In the Plasma Protease C1-inhibitor market, major players are focusing on various market strategies such as high research and development activities, partnerships, collaborations, acquisitions, and mergers etc. Major players in the Plasma Protease C1-inhibitor market are CSL Behring LLC., Takeda Pharmaceutical Company Limited, Pharming Technologies B.V., KalVista Pharmaceuticals, Inc amongst others.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • Report customization as per the client's requirements.
  • 3 months of analyst support.
Note: Product cover images may vary from those shown
2 of 4


  • BioCryst Pharmaceuticals
  • Centogene AG
  • CSL Behring LLC.
  • MORE
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Hereditary Angioedema (HAE).
4.2.2 Increasing Investments in the Research & Development activities
4.3 Market Restraints
4.3.1 Lack of Awareness about Plasma protease C1 inhibitors
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Drug
5.1.1 C1-inhibitors
5.1.2 Kallikrein Inhibitor
5.1.3 Selective Bradykinin B2 Receptor Antagonist
5.2 By Dosage Form
5.2.1 Lyophilized
5.2.2 Injectable
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa
5.3.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 CSL Behring LLC.
6.1.2 Takeda Pharmaceutical Company Limited (Shire Pharmaceutical Holdings)
6.1.3 Ionis Pharmaceuticals, Inc.
6.1.4 Pharming Technologies B.V.
6.1.5 Centogene AG
6.1.6 BioCryst Pharmaceuticals
6.1.7 KalVista Pharmaceuticals, Inc.

Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • CSL Behring LLC.
  • Takeda Pharmaceutical Company Limited (Shire Pharmaceutical Holdings)
  • Ionis Pharmaceuticals, Inc.
  • Pharming Technologies B.V.
  • Centogene AG
  • BioCryst Pharmaceuticals
  • KalVista Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown